Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[STI571: a summary of targeted therapy].

Postepy higieny i medycyny doswiadczalnej (Online) - 1 Jan 2006

Czyz Małgorzata, Jakubowska Justyna

Abstract excerpt

STI571 (imatinib; Gleevec) was developed as the first molecularly targeted therapy. It was the result of an extensive search for molecules to block the aberrant activity of Abl kinase in the fusion protein Bcr-Abl. In addition, it can specifically inhibit the activity of c-Kit and PDGF receptors. This orally bioavailable drug has a low toxicity profile. It is approved to treat the patients with chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Tolerance
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Inhibitory Concentration 50

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Source

Identifiers

PMID: 17245318

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[STI571: a summary of targeted therapy].PMID 17245318Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaSemantic proximity Read ↗

[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].Semantic proximity Read ↗

The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).Semantic proximity Read ↗

Clinical management of gastrointestinal stromal tumors: before and after STI-571.Semantic proximity Read ↗

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Semantic proximity Read ↗

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336Semantic proximity Read ↗

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Semantic proximity Read ↗

Molecular targets in acute myelogenous leukemia.Semantic proximity Read ↗

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571Semantic proximity Read ↗

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.